ASBMT News  by unknown
PHYSICAN AT MASS. GENERAL
COMPLETES GVHD RESEARCH
The recipient of a New Investigator
Award from ASBMT and Orphan
Medical, Inc., has submitted a final
report on his research concerning
bone marrow transplant failures in
patients with leukemia and other
blood diseases.
Yong-Guang Yang, MD, PhD, an
assistant professor in surgery at Mas-
sachusetts General Hospital, Boston,
has been seeking ways to limit the
incidence of graft-versus-host disease
(GvHD). He and his team have been
evaluating the use of the cytokine in-
terleukin-12 (IL-12) to prevent or limit
GvHD.
Studies in mice undergoing bone
marrow transplantation have shown
that a single injection of IL-12 reduced
GvHD while maintaining the graft-
versus-leukemia (GvL) effect. These
benefits appear related to changes in
another cytokine, interferon- (IFN-).
Further studies suggest that IFN- is
the key to separating the GvH from
the GvL effects of bone marrow trans-
plantation, mainly through its effects
on CD8 T cells.
Additional animal studies, designed
to more closely resemble conditions
in human bone marrow transplanta-
tion, are suggesting that IFN- plays
an important role in inducing apopto-
sis, or programmed cell death, of ac-
tivated T cells. Dr. Yang and col-
leagues plan further work to identify
the other factors that are likely in-
volved in the effects of IFN- on GvH
and GvL activity.
NEW INVESTIGATOR EVALUATES
CANCER CELL DIFFERENTIATION
The recipient of a New Investigator
Award from ASBMT and Roche Labo-
ratories has submitted a mid-project
progress report on his work in differ-
entiation and destruction of cancer
cells.
Subramaniam Malarkannan, PhD,
assistant professor of medicine at the
Medical College of Wisconsin, Mil-
waukee, and his team have been ex-
ploring the role of natural killer (NK)
cells, one of the first-line-of-defense
cells in the immune response.
His initial step was to look at the
ways in which NK cells distinguish
between “self” and “non-self” cells,
thus knowing which cells to attack.
The research has focused on certain
molecules, or ligands, on the target
cells that could be responsible for turn-
ing on the toxic activity of NK cells.
One particularly important ligand
appears to be a protein called H60,
which occurs in different isoforms, or
protein lengths. Experiments so far
suggest that the full-length H60 pro-
tein may play a central role in the
mechanism by which NK recognizes
cells as “self” rather than “non-self.”
Dr. Malarkannan and his colleagues
plan further studies to clarify the im-
portance of H60 protein length. They
also are studying another molecule
that may contribute to activating the
cell-killing effect of NK cells, a receptor
called NKG2D.
Based on his progress to date,
the $25,000-per-year award for Dr.
Malarkannan’s research has been re-
newed for a second year.
UNIV. OF MINNESOTA PHYSICIAN
COMPLETES T-CELL PROJECT
The recipient of a New Investigator
Award from ASBMT and Fujisawa
Healthcare has submitted a final re-
port on his research on prevention of
graft rejection after bone marrow
transplantation.
Wayne Godfrey, MD, an assistant
professor in the departments of pedi-
atrics and medicine at the University
of Minnesota, Minneapolis, has con-
ducted a two-year project to find new
ways of inducing tolerance in human
T cells in bone marrow preparations
before transplantation.
He and his colleagues have sought
methods of eliminating from trans-
plant specimens the activated T cells
that might contribute to reactions
against foreign cells. A dye was used
to label inactivated T cells, enhancing
the effectiveness of cell-sorting proce-
dures to eliminate the activated cells.
Transplantation of grafts from which
the alloreactive cells have been elimi-
nated may help to prevent graft-ver-
sus-host disease (GvHD).
The researchers also have been
working on new techniques of isolat-
ing and culturing human CD4CD25
cells. Although relatively rare, these reg-
ulatory cells appear to play a central
role in preventing GvHD while main-
taining the leukemia-killing effect of
bone marrow transplants.
Dr. Godfrey’s team are preparing
to publish their results on isolation,
expansion, and characteristics of these
cells, and planning the first clinical
trial of their new techniques.
TANDEM BMT MEETINGS CD
MAILED TO ALL REGISTRANTS
All plenary and concurrent ses-
sions, plus the E. Donnall Thomas
Lecture and the Mortimer M. Bortin
Lecture, are included on an interac-
tive CD-ROM that was mailed in May
to all who registered for the Tandem
BMT Meetings in February in Orlando.
Additional copies are available for
$10 plus $2.50 postage and han-
dling. Please contact the ASBMT
Headquarters Office.
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